Michał ŚwięCh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michał ŚwięCh has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Dariusz Waniczek
Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-514 Katowice, Poland
1 shared publication - Elżbieta Świętochowska
Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry, Medical University of Silesia in Katowice, 40-055 Katowice, Poland
1 shared publication - Justyna Lorenc-Góra
Department of Imaging Diagnostics, St Barbara Regional Specialist Hospital No 5, 41-214 Sosnowiec, Poland
1 shared publication - Małgorzata Muc-Wierzgoń
Department of Propedeutics of Internal Medicine and Emergency Medicine, Medical University of Silesia in Katowice, 41-902 Katowice, Poland
1 shared publication - Paweł Kowalczyk
Department of Animal Nutrition, The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of Sciences, Instytucka 3, 05-110 Jabłonna, Poland
1 shared publication - Zenon Pawel Czuba
Department of Microbiology and Immunology, Medical University of Silesia in Katowice, Jordana 19, 41-808 Zabrze, Poland
1 shared publication
Latest Publications
- Open Access
- 25 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2156
Serum Cytokine Profiles Associated with Inflammation and Tumor Progression in Crohn’s Disease and Colorectal Cancer
Chronic inflammation is a recognized driver of colorectal cancer (CRC) development, particularly in patients with Crohn’s disease (CD). This study aimed to explore serum inflammatory cytokine profiles in patients with Crohn’s disease and colorectal cancer and to assess their associations with disease activity and tumor-related features. Seventy-eight participants were included: 24 with CD, 31 with CRC, and 23 healthy controls. Serum levels of 27 cytokines were measured using the Bio-Plex Pro Human Cytokine 27-plex Assay. Principal component analysis identified three cytokine clusters (factors). Factor 2, comprising IL-9, MIP-1β, and PDGF-β, was significantly elevated in CD patients compared to controls (p < 0.001), showed intermediate levels in CRC patients, and positively correlated with fecal calprotectin (R = 0.44; p = 0.04), indicating an association with local intestinal inflammation. In CRC patients, Factor 1, comprising key Th1/Th17 cytokines (IL-1β, IL-2, IL-4, IL-5, IL-15, IL-17A, FGF-B, GM-CSF, IFN-γ, TNF-α, and VEGF), reflecting pro-inflammatory and cell-mediated immune signaling, correlated with lymph node metastasis (τ = 0.27; p = 0.03), while Factor 2 showed a trend toward a negative correlation with tumor histological grade (τ = −0.22; p = 0.09). Factor 3, encompassing regulatory and hematopoietic cytokines, did not differ significantly between groups (p = 0.21). These findings suggest that IL-9, MIP-1β, and PDGF-β reflect inflammatory activity and may be involved in inflammation-associated tumorigenic processes in the gut. Serum profiling of selected cytokines may provide biologically relevant information and support further investigation of inflammation-associated immune patterns in CD and CRC. Further studies are warranted to validate their clinical utility and to elucidate their mechanistic role in inflammation-driven colorectal carcinogenesis.
- 25 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2156
Open AccessSerum Cytokine Profiles Associated with Inflammation and Tumor Progression in Crohn’s Disease and Colorectal Cancer
Chronic inflammation is a recognized driver of colorectal cancer (CRC) development, particularly in patients with Crohn’s disease (CD). This study aimed to explore serum inflammatory cytokine profiles in patients with Crohn’s disease and colorectal cancer and to assess their associations with disease activity and tumor-related features. Seventy-eight participants were included: 24 with CD, 31 with CRC, and 23 healthy controls. Serum levels of 27 cytokines were measured using the Bio-Plex Pro Human Cytokine 27-plex Assay. Principal component analysis identified three cytokine clusters (factors). Factor 2, comprising IL-9, MIP-1β, and PDGF-β, was significantly elevated in CD patients compared to controls (p < 0.001), showed intermediate levels in CRC patients, and positively correlated with fecal calprotectin (R = 0.44; p = 0.04), indicating an association with local intestinal inflammation. In CRC patients, Factor 1, comprising key Th1/Th17 cytokines (IL-1β, IL-2, IL-4, IL-5, IL-15, IL-17A, FGF-B, GM-CSF, IFN-γ, TNF-α, and VEGF), reflecting pro-inflammatory and cell-mediated immune signaling, correlated with lymph node metastasis (τ = 0.27; p = 0.03), while Factor 2 showed a trend toward a negative correlation with tumor histological grade (τ = −0.22; p = 0.09). Factor 3, encompassing regulatory and hematopoietic cytokines, did not differ significantly between groups (p = 0.21). These findings suggest that IL-9, MIP-1β, and PDGF-β reflect inflammatory activity and may be involved in inflammation-associated tumorigenic processes in the gut. Serum profiling of selected cytokines may provide biologically relevant information and support further investigation of inflammation-associated immune patterns in CD and CRC. Further studies are warranted to validate their clinical utility and to elucidate their mechanistic role in inflammation-driven colorectal carcinogenesis.